CREDENCE (2019) — Trial Summary
CREDENCE (2019): Phase 3 randomized, double-blind, placebo-controlled trial of canagliflozin 100 mg once daily versus placebo in adults with type 2 diabetes and albuminuric CKD (eGFR 30–<90 mL/min/1.73 m², UACR >300–5000 mg/g) on a stable ACE inhibitor or ARB (NCT02065791). Primary composite: end-st
References
- Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295-2306.